These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 31957067)

  • 41. Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies:
    Brown JR; Ghia P; Jurczak W; Kahl BS; Lamanna N; Robak T; Shadman M; Tam CS; Qiu L; Paik J; Salmi T; Wang L; Zhang J; Zhang M; Cohen A; Ma H; Tedeschi A
    Haematologica; 2024 Jul; 109(7):2277-2283. PubMed ID: 38426293
    [No Abstract]   [Full Text] [Related]  

  • 42. Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
    Ozbagcivan O; Akarsu S; Nazli EC; Lebe B; Fetil E
    Ann Hematol; 2021 Jan; 100(1):293-294. PubMed ID: 32221651
    [No Abstract]   [Full Text] [Related]  

  • 43. Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
    Morabito F; Tripepi G; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Bossio S; Varettoni M; Murru R; Chiarenza A; Visentin A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Al-Janazreh H; Vigna E; Martino EA; Mendicino F; Cassin R; D'Arrigo G; Galimberti S; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Neri A; Fronza G; Monti P; Menichini P; Cutrona G; Jaksic O; Rossi D; Di Raimondo F; Cuneo A; Gaidano G; Polliack A; Trentin L; Foà R; Ferrarini M; Gattei V; Gentile M
    Eur J Haematol; 2021 Apr; 106(4):493-499. PubMed ID: 33378569
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bruton's tyrosine kinase inhibitors and the kidney: Focus on ibrutinib.
    Brener ZZ; Brener H; Losev A
    J Oncol Pharm Pract; 2020 Oct; 26(7):1735-1737. PubMed ID: 32054411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
    McCulloch R; Lewis D; Crosbie N; Eyre TA; Bolam S; Arasaretnam A; Creasey T; Goradia H; McMillan A; Dawi S; Harrison S; Miles O; Robinson A; Dutton D; Wilson MR; McKay P; Follows G; Phillips N; Patmore R; Lambert J; Bishton M; Osborne W; Johnston R; Kirkwood AA; Rule S
    Br J Haematol; 2021 Apr; 193(2):290-298. PubMed ID: 33620106
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel agents versus chemotherapy as frontline treatment of CLL.
    Piggin A; Bayly E; Tam CS
    Leuk Lymphoma; 2017 Jun; 58(6):1320-1324. PubMed ID: 28271950
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
    Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
    Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
    Varma G; Johnson TP; Advani RH
    Clin Adv Hematol Oncol; 2016 Jul; 14(7):543-54. PubMed ID: 27379948
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
    Visentin A; Imbergamo S; Scomazzon E; Pravato S; Frezzato F; Bonaldi L; Pizzi M; Vio S; Gregianin M; Burei M; Facco M; Semenzato G; Piazza F; Trentin L
    Br J Haematol; 2019 Apr; 185(1):193-197. PubMed ID: 29974955
    [No Abstract]   [Full Text] [Related]  

  • 50. The new life of ibrutinib therapy in CLL: enhancing personalized approaches.
    Molica S; Mauro FR
    Expert Rev Anticancer Ther; 2024 Sep; 24(9):789-792. PubMed ID: 38993050
    [No Abstract]   [Full Text] [Related]  

  • 51. The use of ibrutinib in chronic lymphocytic leukemia.
    Damon LE
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):154-6. PubMed ID: 27058026
    [No Abstract]   [Full Text] [Related]  

  • 52. Overall survival of patients with CLL treated with ibrutinib in the first line compared to second-line ibrutinib after chemotherapy/chemoimmunotherapy.
    Robak T; Doubek M; Ferrant E; Diels J; Andersone L; Wilbertz S; Healy NC; Neumayr L; van Sanden S
    Curr Med Res Opin; 2024 Aug; 40(8):1369-1378. PubMed ID: 38885086
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study.
    Gerhardt A; Dörfel S; Schulz H; Schlag R; Vornholz L; Nejad-Asgari S; Welslau M
    Eur J Haematol; 2024 Jun; 112(6):927-937. PubMed ID: 38342972
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib.
    Cramer P; Langerbeins P; Hallek M
    Cancer J; 2016; 22(1):62-6. PubMed ID: 26841018
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A New Scoring System for the Evaluation of Ibrutinib-Associated Arrhythmias in Chronic Lymphocytic Leukemia: The ACEF Score.
    Koyuncu İ; Koyuncu B; Uğur MC; Koyun E; Şenöz O; Doğduş M; Bilgir O
    Turk J Haematol; 2024 May; 41(2):91-96. PubMed ID: 38721568
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment.
    Gallais F; Ysebaert L; Despas F; De Barros S; Obéric L; Allal B; Chatelut E; White-Koning M
    Clin Pharmacol Ther; 2021 Jul; 110(1):220-228. PubMed ID: 33539551
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis.
    Ronconi G; Dondi L; Calabria S; Piccinni C; Pedrini A; Esposito I; Martini N
    Clin Drug Investig; 2021 Jul; 41(7):595-604. PubMed ID: 34032988
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incidence of invasive fungal infections in patients with chronic lymphocytic leukemia receiving ibrutinib within the veteran's healthcare administration.
    Walker C; Horowitz A; Nooruddin Z; Frei CR
    J Oncol Pharm Pract; 2024 Jun; 30(4):673-677. PubMed ID: 37309168
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Concomitant autoimmune hemolytic anemia and pure red cell aplasia in a patient with chronic lymphocytic leukemia successfully treated with ibrutinib.
    Krečak I; Čengić M; Skorić I; Nakić M; Gverić-Krečak V
    Ann Hematol; 2021 Nov; 100(11):2861-2862. PubMed ID: 34109444
    [No Abstract]   [Full Text] [Related]  

  • 60. Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia.
    Innocenti I; Autore F; Pasquale R; Morelli F; Efremov DG; Laurenti L
    Expert Rev Hematol; 2017 Dec; 10(12):1069-1076. PubMed ID: 29082795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.